CN114831961B - Liver-targeted bionic cell membrane drug-loaded nano-particle and preparation method and application thereof - Google Patents
Liver-targeted bionic cell membrane drug-loaded nano-particle and preparation method and application thereof Download PDFInfo
- Publication number
- CN114831961B CN114831961B CN202210347880.4A CN202210347880A CN114831961B CN 114831961 B CN114831961 B CN 114831961B CN 202210347880 A CN202210347880 A CN 202210347880A CN 114831961 B CN114831961 B CN 114831961B
- Authority
- CN
- China
- Prior art keywords
- cell membrane
- drug
- liver
- targeted
- loaded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 114
- 210000000170 cell membrane Anatomy 0.000 title claims abstract description 81
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 229940079593 drug Drugs 0.000 title claims abstract description 57
- 239000011664 nicotinic acid Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims abstract description 34
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract description 30
- 229930002330 retinoic acid Natural products 0.000 claims abstract description 28
- 108700012411 TNFSF10 Proteins 0.000 claims abstract description 22
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 22
- 230000002018 overexpression Effects 0.000 claims abstract description 8
- 241000713666 Lentivirus Species 0.000 claims abstract description 7
- 229920001577 copolymer Polymers 0.000 claims abstract description 5
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 17
- 239000001963 growth medium Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 10
- 239000004417 polycarbonate Substances 0.000 claims description 10
- 229920000515 polycarbonate Polymers 0.000 claims description 10
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 10
- 230000003592 biomimetic effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000013592 cell lysate Substances 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000001085 differential centrifugation Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 239000008055 phosphate buffer solution Substances 0.000 claims description 4
- 239000012266 salt solution Substances 0.000 claims description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 3
- 229940122907 Phosphatase inhibitor Drugs 0.000 claims description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 3
- 230000003698 anagen phase Effects 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000004945 emulsification Methods 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 239000013049 sediment Substances 0.000 claims description 3
- 238000003153 stable transfection Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 230000002934 lysing effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 abstract description 4
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract description 3
- 230000035161 fibroblast apoptotic process Effects 0.000 abstract description 3
- 210000004024 hepatic stellate cell Anatomy 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000002440 hepatic effect Effects 0.000 abstract description 2
- 210000005228 liver tissue Anatomy 0.000 abstract description 2
- 238000001890 transfection Methods 0.000 abstract 1
- 239000000835 fiber Substances 0.000 description 24
- 102000008186 Collagen Human genes 0.000 description 21
- 108010035532 Collagen Proteins 0.000 description 21
- 229920001436 collagen Polymers 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 230000008021 deposition Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 230000008685 targeting Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000003995 blood forming stem cell Anatomy 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 3
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 3
- 238000003235 crystal violet staining Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000013424 sirius red staining Methods 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- -1 TM-NP) Substances 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002539 nanocarrier Substances 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091008005 TRAIL–DR complexes Proteins 0.000 description 1
- 102100031344 Thioredoxin-interacting protein Human genes 0.000 description 1
- 101710114149 Thioredoxin-interacting protein Proteins 0.000 description 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 1
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a liver-targeted bionic cell membrane drug-loaded nanoparticle, a preparation method and application thereof, wherein the outside of the drug-loaded nanoparticle is coated by an engineering cell membrane, and an anti-liver fibrosis drug is encapsulated in the drug-loaded nanoparticle for treating liver fibrosis. The engineering cell membrane selects LX2 cells (human hepatic stellate cells) as source cells, and specifically expresses tumor necrosis factor related apoptosis-inducing ligand (TRAIL) protein through Lv-TRAIL-zsgreen over-expression lentivirus transfection. The drug-loaded nano-particles consist of lactic acid-glycolic acid copolymer (PLGA) and all-trans retinoic acid (ATRA), and the ATRA and TRAIL can exert synergistic effect to induce hepatic fibroblast apoptosis. The bionic cell membrane nano particles are mainly concentrated in liver tissues after entering the body, and have remarkable treatment effect in anti-hepatic fibrosis treatment, realize targeted delivery and efficient synergistic effect, and have wide application prospects.
Description
Technical Field
The invention belongs to the field of pharmaceutical preparations, and in particular relates to liver-targeted bionic cell membrane drug-loaded nano-particles, and a preparation method and application thereof.
Background
Activation of hepatic stellate cells (Hepatic Stellate Cells, HSC) is an effector of liver fibrosis and thus its continued progression leading to the development of cirrhosis and hepatocellular carcinoma. As the most important mesenchymal cells in the liver, HSCs are normally in a resting state in the liver, storing vitamin a in the form of retinol esters. Following liver injury, HSCs activate extracellular matrix such as alpha-smooth muscle actin (alpha-smooth muscle actin, alpha-SMA) and I, III type collagen fibers. The increased number of fibroblasts and excessive deposition of extracellular matrix proteins disrupt the normal structure of the liver further leads to liver fibrosis. Whereas retinoic acid loss may play a potential role in promoting cell activation, related derivatives of vitamin a help prevent liver fibrosis and carcinogenesis. ATRA as one of the activated products of vitamin a can inhibit HSC activation by inhibiting thioredoxin interacting protein expression, thereby reducing its oxidative stress level to play a therapeutic role.
In recent years, a bionic cell membrane nano-drug delivery system gradually realizes innovative application in a plurality of fields such as vaccine preparation, disease targeted therapy and the like. The genetically engineered cell membrane has higher biocompatibility and biological safety, can reduce the serial immune reactions such as opsonin and complement activation caused by exogenous substances entering the body, and effectively avoid capturing drugs by a mononuclear macrophage system. In addition, the engineering cells select LX2 cells, and can express specific proteins on cell membranes, so that the bionic nano-carrier has heterologous targeting characteristics, and simultaneously activates downstream Caspase cascade reaction and NF- κB and JNK/AP signal channels to induce corresponding fibroblast apoptosis through the combination of TRAIL proteins and death receptor DR 5.
The bionic cell membrane drug-loaded nano-particles are different from widely applied red cell membrane coated bionic nano-materials, and the functional therapeutic proteins are expressed on the cell membrane through genetic engineering design except for selection of cell types, so that the extension application of the bionic nano-system is further realized. The liver-targeted bionic cell membrane drug-loaded nano-particles can be used as an effective strategy for treating liver fibrosis, and a new idea is provided for treating tumors.
Disclosure of Invention
The invention aims at overcoming the defects of the prior art and provides a liver-targeted bionic cell membrane drug-loaded nanoparticle, and a preparation method and application thereof.
The aim of the invention is achieved by the following technical scheme:
in a first aspect, the invention provides a preparation method of liver-targeted bionic cell membrane drug-loaded nanoparticles, which comprises the following steps:
(1) Preparing drug-loaded nano-particles: dissolving a lactic acid-glycolic acid copolymer and all-trans retinoic acid in anhydrous dichloromethane, wherein the mass ratio of the lactic acid-glycolic acid copolymer to the all-trans retinoic acid is 8-10:1, using polyvinyl alcohol as an aqueous phase, and preparing the aqueous phase by dissolving the polyvinyl alcohol in deionized water, wherein 4g of the polyvinyl alcohol is added into every 100ml of deionized water; then emulsifying on ice by using probe ultrasound under the condition that the output power is 260-325W and the duration is 5-15min; slowly dripping the white emulsion formed by ultrasonic emulsification into 12-14mL of single distilled water, stirring for 4-5h at room temperature to volatilize dichloromethane and solidify the drug-loaded nano particles; finally, the drug-loaded nano particles are collected after ultrafiltration and centrifugation for 30min at 3000 rpm;
(2) Preparation of LX2cell line stably expressing TRAIL protein: culturing LX2 cells in a logarithmic growth phase until the cells adhere to the wall, then transfecting the LX2 cells by using a culture medium containing Lv-TRAIL-zsgreen over-expression lentivirus, culturing for 24 hours at 37 ℃, replacing the culture medium containing the Lv-TRAIL-zsgreen over-expression lentivirus by using a DMEM culture medium for further culturing for 48 hours, and then performing resistance screening by using a G418 culture medium containing 200 mu mol/L to obtain a LX2cell line which can stably express TRAIL protein by stable transfection;
(3) Preparation of engineered cell membranes: washing the LX2cell line which is prepared in the step (1) and stably expresses TRAIL protein in a phosphate buffer solution at 4 ℃ for three times, re-suspending the cell line by using hypotonic cell lysate, then lysing the cell line on a shaker at 4 ℃ for 4-6 hours, outputting 260-325W of power, and performing ultrasonic treatment on the cell line by a probe for 1-3 minutes; then, differential centrifugation is carried out to extract cell membrane precipitation; finally, re-suspending the proposed cell membrane sediment by using phosphate buffer salt solution, and extruding the cell membrane suspension back and forth from the polycarbonate membrane for 9-13 times by a micro extruder to obtain an engineering cell membrane;
(4) Preparing liver-targeted bionic cell membrane drug-loaded nano-particles: and (3) carrying out ultrasonic treatment on the engineering cell membrane prepared in the step (3), then blending the engineering cell membrane with the drug-carrying nano-particles prepared in the step (1) according to the mass ratio of 1:1, and extruding the blending liquid back and forth from a 200 nm-aperture polycarbonate membrane for 9-12 times through a micro extruder to obtain the liver-targeted bionic cell membrane drug-carrying nano-particles.
Further, the differential centrifugation in step (3) includes: firstly, centrifuging for 10-15min under the centrifugal force of 1,000-1500g and the centrifugal condition of 4 ℃, and taking supernatant; centrifuging supernatant at 10000-12000g centrifugal force and 4deg.C for 30-40min; finally, the mixture is centrifuged for 1 to 3 hours under the centrifugal force of 900000 to 100000g and the centrifugal condition of 4 ℃.
Further, the hypotonic cell lysate comprises a 0.25 x phosphate buffered saline solution, a protease inhibitor, and a phosphatase inhibitor.
Further, the polycarbonate membrane in step (3) has a pore size of 50nm, 100nm, 200nm or 400nm.
Further, the polycarbonate membrane pore size is preferably 200nm.
In a second aspect, the invention provides liver-targeted bionic cell membrane drug-loaded nano-particles prepared by the method.
In a third aspect, the invention provides an application of liver-targeted bionic cell membrane drug-loaded nano-particles in preparing drugs for treating liver fibrosis.
The invention has the beneficial effects that: 1. the invention provides bionic cell membrane drug-loaded nano-particles capable of playing a synergistic targeting role to treat hepatic fibrosis. Liver targeting can be achieved by using LX2 cells as source cells. The therapeutic protein TRAIL expressed on the cell membrane can promote the activation of hepatic fibroblast apoptosis, and the activation inhibition of the drug ATRA on the fibroblast can effectively reduce the promotion of hepatic fibrosis. Meanwhile, the bionic cell membrane drug-loaded nano-particles are conveyed by virtue of a stable membrane structure, so that the residence time of the bionic cell membrane drug-loaded nano-particles in blood circulation can be prolonged, the bionic cell membrane drug-loaded nano-particles smoothly reach target cells, and effective permeation and treatment of drugs are realized;
2. the polymer material used by the engineering cell membrane nano-particles is PLGA, and the PLGA is used as a medical polymer material approved by the United states Food and Drug Administration (FDA) to ensure the safety of a drug delivery system, and has higher clinical application value with the coated cell membrane for reinforcing the biocompatibility.
Drawings
FIG. 1 is a schematic diagram of the preparation and structure of a liver-targeted biomimetic cell membrane drug-loaded nanoparticle;
FIG. 2 is a transmission electron microscope image of a liver-targeted biomimetic cell membrane drug-loaded nanoparticle;
FIG. 3 is a Western blot assay;
FIG. 4 is a graph showing the effect of detecting TM-ATRA/NP and NP, M-NP, ATRA/NP, M-ATRA/NP, and TM-NP induced apoptosis by crystal violet;
FIG. 5 is a graph showing the detection of apoptosis induced by TM-ATRA/NP and TM-NP by classical collagen fiber staining;
FIG. 6 is a graph showing the detection of TM-ATRA/NP and TM-NP-induced apoptosis by sirius red staining;
FIG. 7 is a graph showing the detection of TM-ATRA/NP and TM-NP-induced apoptosis by hematoxylin-eosin staining;
fig. 8 is a schematic diagram of HE staining of tissue sections of different organs to assess treatment safety.
Detailed Description
For the purposes of making the objects, technical solutions and advantages of the present invention more apparent, the present invention will be further described in detail with reference to the accompanying drawings and examples, it being understood that the specific examples described herein are for the purpose of illustrating the present invention only, and not all the examples. All other embodiments, which can be made by those skilled in the art based on the embodiments of the present invention without making any inventive effort, are within the scope of the present invention.
FIG. 1 is a schematic diagram of preparation and structure of a liver-targeted biomimetic cell membrane drug-loaded nanoparticle (TM-ATRA/NP) of the present invention.
The present invention is further described below with reference to the accompanying drawings, in which the embodiments described in the present specification are merely examples of implementation forms of the inventive concept, and the scope of protection of the present invention should not be construed as being limited to the specific forms set forth in the embodiments, but also equivalent technical means as will occur to those skilled in the art based on the inventive concept.
The experimental methods described in the following examples are all conventional methods unless otherwise specified; the reagents and materials, as described herein without any knowledge, are commercially available.
Example preparation of liver-targeting bionic cell membrane drug-loaded nanoparticle (TM-ATRA/NP)
(1) Preparation of drug-loaded nanoparticles (ATRA/NP)
10mg of all-trans retinoic acid (ATRA) and 100mg of lactic-co-glycolic acid (PLGA) were blended in 1mL of anhydrous methylene chloride, and 4% polyvinyl alcohol (PVA) was used as the aqueous phase prepared by dissolving polyvinyl alcohol in deionized water, and 4g of polyvinyl alcohol was added to every 100mL of deionized water; then emulsifying on ice by using probe ultrasound under the condition that the output power is 325W and the power is 720W for 15min; slowly dripping the white emulsion formed by ultrasonic emulsification into 14mL of single distilled water, and stirring for 5 hours at room temperature to volatilize dichloromethane and solidify drug-loaded nano particles (ATRA/NP); finally, the drug-loaded nano particles (ATRA-loaded nanoparticles, ATRA/NP) are collected after ultrafiltration and centrifugation at 3000rpm for 30min;
(2) Preparation of LX2cell line (LX 2-TRAIL-zsgreen) stably expressing TRAIL protein
Culturing LX2 cells in a logarithmic growth phase until the cells adhere to the wall, then transfecting the LX2 cells by using a culture medium containing Lv-TRAIL-zsgreen over-expression lentivirus, culturing for 24 hours at 37 ℃, replacing the culture medium containing the Lv-TRAIL-zsgreen over-expression lentivirus by using a fresh culture medium, continuously culturing for 48 hours, wherein the cell fusion degree in each hole reaches about 90%, and then performing resistance screening by using a G418 culture medium containing 200 mu mol/L to obtain a LX2cell line (LX 2-TRAIL-zsgreen) which can stably express TRAIL protein by stable transfection;
the fresh culture medium is a DMEM culture medium;
the Lv-TRAIL-zsgreen over-expression slow virus is from Shanghai Ji Kai gene medical science and technology Co., ltd, comprises a gene fragment capable of expressing TRAIL protein and a gene fragment capable of expressing zsgreen fluorescent protein.
(3) Preparation of engineered cell membranes (LX 2-zsgreen-trail cell membrane)
Washing the LX2cell line (LX 2-TRAIL-zsgreen) which is prepared in the step (1) and stably expresses TRAIL protein in phosphate buffer saline solution at 4 ℃ for three times, re-suspending the cell line by hypotonic cell lysate, then cracking the cell line on a shaking table at 4 ℃ for 4 hours, and then using a probe with output power of 260W for 1min; then, differential centrifugation is carried out to extract cell membrane precipitation; the differential centrifugation includes: firstly, centrifuging for 10min under the centrifugal force of 1000g and the centrifugal condition of 4 ℃, and taking supernatant; centrifuging supernatant at 10000g centrifugal force and 4deg.C for 30min; finally, under the centrifugal force of 100000g and the centrifugal condition of 4 ℃, the transparent cell membrane sediment is obtained after centrifugation for 1 h; finally, the proposed cell membrane pellet was resuspended in phosphate buffered saline, and the cell membrane suspension was squeezed back and forth 11 times from 200nm pore size polycarbonate membrane by a micro-extruder to give an engineered cell membrane (LX 2-zsgreen-trail cell membrane).
The hypotonic cell lysate comprises 0.25 x phosphate buffer salt solution, protease inhibitor and phosphatase inhibitor.
(4) Preparation of liver-targeted bionic cell membrane drug-loaded nano-particles (TM-ATRA/NP)
And (3) carrying out ultrasonic treatment on 10mg of the engineering cell membrane (LX 2-zsgreen-trail cell membrane) prepared in the step (3), then blending with 10mg of the drug-loaded nano-particles (ATRA/NP) prepared in the step (1), and extruding the blending liquid back and forth from a 200 nm-aperture polycarbonate membrane for 11 times through a micro extruder to obtain the liver-targeted bionic cell membrane drug-loaded nano-particles (TM-ATRA/NP).
FIG. 2 is a transmission electron microscopy image of liver-targeted biomimetic cell membrane drug-loaded nanoparticles (TM-ATRA/NP); the liver-targeted bionic cell membrane drug-loaded nano-particles prepared by the invention in figure 2 are spherical particles and have a classical core-shell structure.
FIG. 3 is a Western blot analysis. The membrane protein concentrations of LX2cell lysate (LX 2cell lysate, CL), LX2cell line lysate stably expressing TRAIL protein (LX 2-TRAIL-zsgreen CL), LX2cell membrane (LX 2cell membrane) and engineered cell membrane (LX 2-zsgreen-TRAIL cell membrane) were measured using BCA kit, respectively, and it can be seen that LX2cell line lysate stably expressing TRAIL protein (LX 2-TRAIL-zsgreen CL) and engineered cell membrane (LX 2-zsgreen-TRAIL cell membrane) all expressed TRAIL protein as shown in fig. 3.
Application example 1
(1) Cytotoxicity test
The crystal violet dyeing detection process comprises the following steps: inoculating Huh7 cells into a 12-well plate according to the number of 5X 10-4 cells/well, culturing for 12 hours, and standing for cell attachment; medium treatments of 24h containing no-nanoparticle treated cells, empty Nanoparticle (NP) cell membrane-coated empty nanoparticle (nanoparticles coated with fibroblast membrane, M-NP), TRAIL protein-expressing cell membrane-coated empty nanoparticle (nanoparticles coated with TRAIL-expressing fibroblast membrane, TM-NP), drug-loaded nanoparticle (ATRA-encapsulated nanoparticles, ATRA/NP), cell membrane-coated ATRA-loaded nanoparticle (ATRA-encapsulated nanoparticles coated with fibroblast membrane, M-ATRA/NP), and liver-targeted biomimetic cell-loaded nanoparticle (ATRA-encapsulated nanoparticles coated with TRAIL-expressing fibroblast membrane, TM-ATRA/NP) were used as experimental groups for Huh7 cells, and fresh medium treatments were used as control groups (control) for Huh7 cells, respectively; then the culture medium containing NP, M-NP, TM-NP, ATRA/NP, M-ATRA/NP or TM-ATRA/NP is discarded, and after washing twice with phosphate buffer solution, the plates are placed on filter paper in an inverted manner, and the water is drained; to the wells of 6 experimental groups (NP, M-NP, TM-NP, ATRA/NP, M-ATRA/NP, or TM-ATRA/NP) and one control group (control), 50. Mu.L of crystal violet staining solution was added per well and incubated at room temperature on a shaker at a frequency of 20 oscillations per minute for 20min. Discarding crystal violet staining solution in the plate, washing with phosphate buffer solution for four times, pouring the plate on filter paper, draining water, and observing cells under a microscope; the detection results are shown in FIG. 4.
FIG. 4 is a graph showing the effects of detection of TM-ATRA/NP and apoptosis induced by NP, M-NP, TM-NP, ATRA/NP, and M-ATRA/NP by crystal violet staining solution. As can be seen from fig. 4, TRAIL cell membranes themselves have an apoptotic effect. The cytotoxicity of TM-ATRA/NP was maximal, indicating that ATRA could synergistically potentiate the cell killing effect of TRAIL.
(2) Liver fibrosis experiment
A mouse liver fibrosis model was constructed. CCl4 was dissolved in corn oil in a 1:4 ratio, and corresponding doses were given to mice according to the weight of the mice in a proportion of 0.5. Mu.L/g of the volume of CCl4, but for practical reasons (range of the syringe) mice were intraperitoneally injected with a constant volume of 50. Mu.L, with the remaining volume being made up with corn oil. Intraperitoneal injections were given every 7 days and weighed in time. Mice were treated with Phosphate Buffered Saline (PBS), TM-NP, ATRA/NP, and TM-ATRA/NP, respectively, and the mice from each group were weighed and averaged.
FIG. 5 is the effect of staining TM-ATRA/NP with control vector TM-NP, ATRA/NP on a mouse liver fibrosis model by classical collagen fiber staining method (Masson) to induce apoptosis. As can be seen from the experimental results, the control group, i.e. healthy mice not receiving treatment, had no obvious blue collagen fibers, indicating that the liver was healthy, whereas the PBS group had a large amount of blue collagen fiber deposited, extending outward from the periphery of the manifold area, the fibrids were thicker and stained darker, indicating that collagen fibers were more, false lobules had formed, indicating that liver fibrosis was severe, and no therapeutic effect. While the TM-NP group had some blue fibril deposition extending outward from around the manifold region, but had some therapeutic effect compared to the PBS group. The ATRA/NP group showed significant blue fibril deposition, but with time the blue fibril decreased, indicating a certain therapeutic effect. Collagen fibers were far less in the TM-ATRA/NP group than in the other groups, indicating that the liver-targeted biomimetic cell membrane drug-loaded nanoparticles (TM-ATRA/NP) were most pronounced to reduce collagen fiber deposition.
FIG. 6 is the effect of detecting TM-ATRA/NP on a mouse liver fibrosis model by sirius red staining with control vector TM-NP and ATRA/NP induced apoptosis. Sirius red staining showed that various types of collagen fibers spread outward from the manifold region, and collagen deposition and spread were observed under polariscope to form prosthetic leaflets, with a large amount of red type I collagen fibers, a small amount of open mesh type II collagen fibers, and yellowish type IV collagen fibers. As can be seen from the experimental results, the control group, i.e. healthy mice not receiving treatment, have no yellow collagen fibers deposited, and the red collagen fibers are less and less stained, which indicates that the liver is healthy and has no liver fibrosis. The PBS group has a large amount of red and faint yellow collagen fibers deposited, and extends outwards from the periphery of a manifold area, and the fiber ropes are thicker and are dyed deeply, so that the PBS group has more collagen fibers, which indicates that liver fibrosis is serious and has no treatment effect. While the TM-NP group had some red collagen fiber deposition, there was still some fibrosis compared to the control group and some therapeutic effect compared to the PBS group. The ATRA/NP group was similar to the TM-NP group, and red collagen fiber deposition was reduced compared to the PBS group, indicating a therapeutic effect. Collagen fibers in the TM-ATRA/NP group are far less than those in other groups, which indicates that liver-targeted bionic cell membrane drug-loaded nano particles (TM-ATRA/NP) have remarkable treatment effect in the liver fibrosis process, and collagen fiber deposition is remarkably reduced.
FIG. 7 shows the effect of detecting TM-ATRA/NP on the control vector TM-NP, ATRA/NP on apoptosis induction by Hematoxylin (hemaloxin) -Eosin (Eosin) staining on the mouse liver fibrosis model. The control group, i.e., healthy mice not receiving treatment, was found to have no apparent tubular structure, indicating no liver fibrosis. The liver slice tissue structure of the PBS group is shown that liver lobule and manifold area structures are not obvious, a large amount of collagen fibers are generated, and the liver slice tissue structure is connected with and surrounds liver cell groups to form a ring-shaped and non-uniform artificial lobule structure; the liver cells in the pseudo-leaflet structure are scattered, the chordal arrangement is not obvious, the gap is large, the liver slice presents a large-area pseudo-leaflet tissue structure, and obvious circular vacuoles are visible in the liver cells. While the TM-NP group had some collagen fiber deposition, and had a certain therapeutic effect but no significant effect compared to the PBS group. The reduced deposition of red collagen fibers in the ATRA/NP group compared with the PBS group indicates a certain therapeutic effect. TM-ATRA/NP still shows normal liver tissue structure, which indicates that the liver-targeted bionic cell membrane drug-loaded nano-particles (TM-ATRA/NP) have remarkable effect of treating liver fibrosis.
Organ distribution experiment of nanocarriers: mice that constructed the liver fibrosis model were cervical sacrificed. Taking Heart (Heart), liver (Liver), spleen (Spleen), lung (Lung) and Kidney (Kidney), fixing in 10% neutral formalin for 4h, taking out, dehydrating with conventional ethanol step by step, and embedding with xylene transparent paraffin; after serial sections, conventional xylenes were dewaxed and washed with ethanol to water at various levels. HE staining was performed and the staining results are shown in fig. 8. Fig. 8 is a schematic diagram of HE staining of tissue sections of different organs to assess treatment safety. As can be seen from fig. 8, the groups were found to be indistinguishable and in physiologically normal condition in other organs except for the liver slice staining. Proves the biological safety and liver targeting of the liver targeting bionic cell membrane drug-loaded nano-particles (TM-ATRA/NP).
The liver-targeted bionic cell membrane drug-loaded nanoparticle prepared by the preparation method of the liver-targeted bionic cell membrane drug-loaded nanoparticle can be used for preparing drugs for treating liver fibrosis.
Claims (6)
1. The preparation method of the liver-targeted bionic cell membrane drug-loaded nanoparticle is characterized by comprising the following steps of:
(1) Preparing drug-loaded nano-particles: dissolving a lactic acid-glycolic acid copolymer and all-trans retinoic acid in anhydrous dichloromethane, wherein the mass ratio of the lactic acid-glycolic acid copolymer to the all-trans retinoic acid is 8-10:1, using polyvinyl alcohol as an aqueous phase, and preparing the aqueous phase by dissolving the polyvinyl alcohol in deionized water, wherein 4g of the polyvinyl alcohol is added into every 100ml of deionized water; then emulsifying on ice by using probe ultrasound under the condition that the output power is 260-325W and the duration is 5-15min; slowly dripping the white emulsion formed by ultrasonic emulsification into 12-14mL of single distilled water, stirring for 4-5h at room temperature to volatilize dichloromethane and solidify the drug-loaded nano particles; finally, the drug-loaded nano particles are collected after ultrafiltration and centrifugation for 30min at 3000 rpm;
(2) Preparation of LX2cell line stably expressing TRAIL protein: culturing LX2 cells in a logarithmic growth phase until the cells adhere to the wall, then transfecting the LX2 cells by using a culture medium containing Lv-TRAIL-zsgreen over-expression lentivirus, culturing for 24 hours at 37 ℃, replacing the culture medium containing the Lv-TRAIL-zsgreen over-expression lentivirus by using a DMEM culture medium for further culturing for 48 hours, and then performing resistance screening by using a G418 culture medium containing 200 mu mol/L to obtain a LX2cell line which can stably express TRAIL protein by stable transfection;
(3) Preparation of engineered cell membranes: washing the LX2cell line which is prepared in the step (2) and stably expresses TRAIL protein in a phosphate buffer solution at 4 ℃ for three times, re-suspending the cell line by using hypotonic cell lysate, then lysing the cell line on a shaker at 4 ℃ for 4-6 hours, outputting 260-325W of power, and performing ultrasonic treatment on the cell line by a probe for 1-3 minutes; then, differential centrifugation is carried out to extract cell membrane precipitation; finally, re-suspending the proposed cell membrane sediment by using phosphate buffer salt solution, and extruding the cell membrane suspension back and forth from the polycarbonate membrane for 9-13 times by a micro extruder to obtain an engineering cell membrane;
the differential centrifugation in step (3) includes: firstly, centrifuging for 10-15min under the centrifugal force of 1,000-1500g and the centrifugal condition of 4 ℃, and taking supernatant; centrifuging supernatant at 10000-12000g centrifugal force and 4deg.C for 30-40min; finally, centrifuging for 1-3h under the centrifugal force of 900000-100000g and the centrifugal condition of 4 ℃;
(4) Preparing liver-targeted bionic cell membrane drug-loaded nano-particles: and (3) carrying out ultrasonic treatment on the engineering cell membrane prepared in the step (3), then blending the engineering cell membrane with the drug-carrying nano-particles prepared in the step (1) according to the mass ratio of 1:1, and extruding the blending liquid back and forth from a 200 nm-aperture polycarbonate membrane for 9-12 times through a micro extruder to obtain the liver-targeted bionic cell membrane drug-carrying nano-particles.
2. The method for preparing liver-targeted biomimetic cell membrane drug-loaded nanoparticles according to claim 1, wherein the hypotonic cell lysate comprises 0.25 x phosphate buffer salt solution, protease inhibitor and phosphatase inhibitor.
3. The method for preparing liver-targeted drug-loaded nanoparticles with bionic cell membrane according to claim 1, wherein the pore diameter of the polycarbonate membrane in the step (3) is 50nm, 100nm, 200nm or 400nm.
4. The method for preparing liver-targeted bionic cell membrane drug-loaded nanoparticles according to claim 3, wherein the pore diameter of the polycarbonate membrane is preferably 200nm.
5. A liver-targeted biomimetic cell membrane drug-loaded nanoparticle prepared by the method of any one of claims 1-4.
6. Use of the liver-targeted biomimetic cell membrane drug-loaded nanoparticle of claim 5 in the preparation of a medicament for treating liver fibrosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210347880.4A CN114831961B (en) | 2022-04-01 | 2022-04-01 | Liver-targeted bionic cell membrane drug-loaded nano-particle and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210347880.4A CN114831961B (en) | 2022-04-01 | 2022-04-01 | Liver-targeted bionic cell membrane drug-loaded nano-particle and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114831961A CN114831961A (en) | 2022-08-02 |
| CN114831961B true CN114831961B (en) | 2023-08-29 |
Family
ID=82563984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210347880.4A Active CN114831961B (en) | 2022-04-01 | 2022-04-01 | Liver-targeted bionic cell membrane drug-loaded nano-particle and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114831961B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015164217A1 (en) * | 2014-04-21 | 2015-10-29 | Theraly Pharmaceuticals Inc. | Trail receptor agonists for treatment of fibrotic diseases |
| CN113925856A (en) * | 2021-10-13 | 2022-01-14 | 郑州大学 | Preparation method and application of bionic nano-drug targeting hepatic stellate cells |
| CN114225027A (en) * | 2021-11-16 | 2022-03-25 | 浙江大学 | Genetically engineered liver cancer targeted cell membrane bionic nano-microsphere and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060275838A1 (en) * | 2003-07-12 | 2006-12-07 | Ranjit Ray | Compositions and methods for inhibiting liver stellate cell growth |
-
2022
- 2022-04-01 CN CN202210347880.4A patent/CN114831961B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015164217A1 (en) * | 2014-04-21 | 2015-10-29 | Theraly Pharmaceuticals Inc. | Trail receptor agonists for treatment of fibrotic diseases |
| CN106573049A (en) * | 2014-04-21 | 2017-04-19 | Theraly制药公司 | TRAIL receptor agonists for treatment of fibrotic diseases |
| CN113925856A (en) * | 2021-10-13 | 2022-01-14 | 郑州大学 | Preparation method and application of bionic nano-drug targeting hepatic stellate cells |
| CN114225027A (en) * | 2021-11-16 | 2022-03-25 | 浙江大学 | Genetically engineered liver cancer targeted cell membrane bionic nano-microsphere and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| Yesi Shi等.TRAIL-expressing cell membrane nanovesicles as an anti-inflammatory platform for rheumatoid arthritis therapy.《Journal of Controlled Release》.2020,第320卷第304-313页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114831961A (en) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106924755B (en) | Activated neutral particle cell membrane coated bionic nano particle and preparation method thereof | |
| Jay et al. | Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation | |
| CN112386709B (en) | Targeting polypeptide modified drug-loaded lipoprotein nano drug delivery system and preparation and application thereof | |
| Jin et al. | Rapid Extracellular Matrix Remodeling via Gene‐Electrospun Fibers as a “Patch” for Tissue Regeneration | |
| CN113952461B (en) | Neutrophil-imitating nano drug delivery system and preparation method and application thereof | |
| CN109666695A (en) | A kind of excretion body carrier and its preparation method and application of targeted integration element α v β 3 | |
| NL2033447B1 (en) | Brain-targeting erythrocyte membrane-enveloped salvianolic acid b nanoparticles as well as preparation method and application thereof | |
| CN115487167B (en) | Preparation of multifunctional bionic nano nerve antidote and application of multifunctional bionic nano nerve antidote in Alzheimer disease treatment medicine | |
| CN111588704B (en) | Targeted responsive release system and preparation method and application thereof | |
| CN113041356A (en) | Hemopsin targeting drug-loading system, preparation method and application thereof | |
| CN113355290A (en) | Anti-tumor engineered exosome, preparation method and application | |
| Ren et al. | Mechanism of miR-30b-5p-Loaded PEG-PLGA nanoparticles for targeted treatment of heart failure | |
| CN114831961B (en) | Liver-targeted bionic cell membrane drug-loaded nano-particle and preparation method and application thereof | |
| Lee et al. | Alveolar macrophage phagocytosis-evading inhaled microgels incorporating nintedanib-PLGA nanoparticles and pirfenidone-liposomes for improved treatment of pulmonary fibrosis | |
| CN111529505B (en) | Functional chimeric apoptotic body and preparation method and application thereof | |
| CN111529504B (en) | Functional chimeric apoptotic body and preparation method and application thereof | |
| CN114668742B (en) | Bacteria-imitating nano medicine delivery system and preparation method and application thereof | |
| CN116286640A (en) | Application of apoptotic bodies in inducing macrophage polarization and promoting wound healing | |
| Hu et al. | Immunomodulatory effect and safety of TNF-α RNAi mediated by oral yeast microcapsules in rheumatoid arthritis therapy | |
| CN107837400A (en) | A kind of novel nano genophore and preparation method thereof | |
| CN114903870B (en) | Engineered cell membrane nano-particles and preparation method and application thereof | |
| Wang et al. | Biomimetic nanoparticles of platelet membranes carrying bFGF and VEGFA genes promote deep burn wound healing | |
| CN115737557B (en) | miR-55 preparation and preparation method and application thereof | |
| CN115779101B (en) | Preparation and application of nanoparticle for resisting tumor metastasis | |
| CN117180443B (en) | Application of cell membrane of synovial myofibroblast in preparation of osteoarthritis medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |